HUTCHMED (China) Limited

NASDAQ:HCM

Drug Manufacturers - Specialty & Generic

Healthcare
$13.99 +1.58%

+$0.16 today

Market cap
$2.44B
Beta
0.37
P/E (TTM)
46.2
EPS (TTM)
$0.05
52W Low $10.01High $19.50

Volume 0.04M

Average 0.04M

HCM Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

HUTCHMED (China) LimitedNASDAQ: HCM

Gross Profit · Q2 FY2025 · quarter ended Jun 2025

Gross profit declines year over year

Q2 FY2025 gross profit of $55.05M fell 12.3% year over year, ahead of the -70.5% change in trailing-twelve-month gross profit. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +22.6% a year.

Context

  • Gross profit amounted to 38.7% of revenue in FY2025, down 6.0 pp from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -12.3% holds above the trailing-twelve-month pace of -70.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2025
$55.05M+0.0% QoQ
Last fiscal yearDec 2025
$212.72M-24.4% YoY
LTMJun 2025
$53.76M-70.5% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-12.3%——
1 year-24.4%——
3-year CAGR+22.6%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
212.72M USD
Year-over-year change
-24.4%
4-year CAGR
+21.4%

Gross Profit vs competitors

How HCM compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -70.5% is the lowest of 9, against a peer median of +2.1%.
  • Gross profit amounts to 8.9% of revenue for HCM, versus a peer median of 84.5%.
HCM Competitors
Gross Profit for HCM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$5.39B USD+26.6%+14.4%92.6%
GMABGenmab A/SLTM Jun 2026$3.84B USD—-38.3%93.0%
EXELExelixis, Inc.LTM Jul 2026$2.35B USD+9.1%+12.9%96.5%
BNTXBioNTech SELTM Jun 2026€1.87B EUR-18.5%-46.9%70.8%
LEGNLegend Biotech CorporationLTM Sep 2026$774.12M USD+40.6%+129.1%57.0%
AAPGAscentage Pharma Group InternationalFY2025CN¥426.75M CNY-55.2%+31.5%76.4%
ZLABZai Lab LimitedLTM Jun 2026$253.9M USD-4.9%+24.0%56.5%
RCUSArcus Biosciences, Inc.LTM Jun 2026$110M USD-58.0%+28.4%94.0%
HCMHUTCHMED (China) LimitedLTM Jun 2025$53.76M USD-70.5%+22.6%8.9%
ANLAdlai Nortye Ltd.LTM Jun 2024$6.49M USD——100.0%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026-$19.69M USD+70.5%+63.7%8.7%
Peer median (excluding HCM) —+2.1%+24.0%84.5%

Competitors are the stored peer set for HCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue356.13M426.41M838M630.2M549.96M
Cost of Revenue258.23M311.1M384.45M348.88M337.24M
Gross Profit97.89M115.31M453.55M281.32M212.72M
Gross Margin27.5%27.0%54.1%44.6%38.7%
Research & Development207.45M267.59M303.06M213.37M164.15M
Selling, General & Admin127.13M136.11M133.18M112.91M103.3M
Operating Expenses426.21M523M436.23M321.93M267.45M
Depreciation & Amortization7.19M8.66M8.21M12.34M13.34M
EBITDA(207.96M)(401.11M)26.58M(31.36M)(41.38M)
EBITDA Margin-58.4%-94.1%3.2%-5.0%-7.5%
Operating Income(328.32M)(409.77M)18.38M(43.71M)(54.73M)
Operating Margin-92.2%-96.1%2.2%-6.9%-10.0%
Interest Income2.08M9.6M36.15M40.08M50.01M
Interest Expense592K652K759K2.87M2.87M
Other Income / Expenses173.19M51.52M87.23M89.07M577.45M
Income Before Tax(155.33M)(360.24M)105.6M45.36M522.72M
Pre-Tax Margin-43.6%-84.5%12.6%7.2%95.0%
Income Tax Expense11.92M(283K)4.51M7.19M63.78M
Net Income(194.65M)(360.84M)100.78M37.73M458.12M
Net Margin-54.7%-84.6%12.0%6.0%83.3%
EPS (Basic)(1.25)(2.15)0.600.222.65
EPS (Diluted)(1.25)(2.15)0.600.222.60
Weighted Avg Shares158.54M169.43M169.93M171.07M171.66M
Weighted Avg Shares (Diluted)158.54M169.43M173.84M174.57M174.58M

HUTCHMED (China) Limited

NASDAQ:HCM

Intrinsic Alpha fair value

Locked

Current Price

$13.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.